Deerfield Management Company, L.P. (Series C) Vaxcyte, Inc. Transaction History

Deerfield Management Company, L.P. (Series C)

$4.76 Billion
Q2 2024

2 transactions

Quarter	Operation	Price Per share	shares change	shares Held	SEC Form
Q1 2023 May 15, 2023	SELL	$36.27 - $47.2 $14.7 Million - $19.1 Million	-405,000 Reduced 57.86%	295,000 $11.1 Million
Q4 2022 Feb 14, 2023	BUY	$20.58 - $47.95 $14.4 Million - $33.6 Million	700,000 New	700,000 $33.6 Million

Others Institutions Holding PCVX

# of Institutions

289

Shares Held

110M

Call Options Held

248K

Put Options Held

109K

Black Rock Inc. New York, NY

9.94M
Shares

$1.05 Billion
0.02% of portfolio
Vanguard Group Inc Valley Forge, PA

9.8M
Shares

$1.03 Billion
0.01% of portfolio
Janus Henderson Group PLC London, X0

8.87M
Shares

$936 Million
0.37% of portfolio
Ra Capital Management, L.P. Boston, MA

8.2M
Shares

$866 Million
9.34% of portfolio
Wellington Management Group LLP Boston, MA

4.59M
Shares

$485 Million
0.06% of portfolio

View Full List

About Vaxcyte, Inc.

Ticker PCVX
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 59,315,100
Market Cap $6.26B
Description
Vaxcyte, Inc., a clinical-stage biotechnology vaccine company, develops novel protein vaccines to prevent or treat bacterial infectious diseases. Its lead vaccine candidate is VAX-24, a 24-valent investigational pneumococcal conjugate vaccine that is in Phase 1/2 clinical trials to treat invasive pneumococcal disease and pneumonia. The company a...

More about PCVX

Track This Portfolio

Portfolio Update

Get notified when there are updates to the investment portfolio of Deerfield Management Company, L.P. (Series C), based on Form 13F filings with the SEC.

News

Stay updated on Deerfield Management Company, L.P. (Series C) with notifications on news.

Account